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There are feweffective, safemodalities for themanagement of
Graves’ ophthalmopathy (GO), a cell-mediated immune co-
morbidity of thyroid disease. Somatostatin analogs inhibit
lymphocyte proliferation and activation, and accumulate in
the orbital tissue of patientswithGO.Adouble-blind, placebo-
controlled study of a long-acting somatostatin analog [16 wk
of long-acting release formulation of octreotide (octreotide-
LAR)] was conducted in 51 patients with mild active GO with
the aim of preventing deterioration and precluding the need
for more aggressive therapeutic modalities, such as glucocor-
ticoids or radiotherapy. No treatment effect was observed for
the primary end point (a composite parameter defining the
outcome as either success or failure on the basis of changes in
class/grade of the severity index and Clinical Activity Scale of
GO). The Clinical Activity Scale score was reduced for pa-
tients treated with octreotide-LAR, but without any signifi-
cant difference with respect to patients receiving placebo.
However, octreotide-LAR significantly reduced proptosis (as
measured by exophthalmometry). This was associated with
nonsignificant differences in favor of octreotide-LAR in a se-
ries of proptosis-related parameters: class III grade, opening
of the upper eyelid, the difference in ocular pressure between
primarypositionandupgaze, andextraocularmuscle involve-
ment. Bymagnetic resonance imaging evaluation the extraoc-
ular muscle volumes appeared reduced, but nonsignificantly.
No significant correlation between the initial uptake of the
somatostatin analog indium-labeledand the response to treat-
ment was observed. One patient in the octreotide-LAR group
developed gallstones. In this study, octreotide-LAR did not
seem suitable to mitigate activity in mild GO. Surprisingly, it
significantly reduced proptosis, one of the most debilitating
symptoms of GO. Additional studies are warranted to define
the benefit to risk ratio of the somatostatin analogs in this
indication. (J Clin Endocrinol Metab 90: 841–848, 2005)
GRAVES’ ORBITOPATHY (GO) is diagnosed in 10–25%of patients with Graves’ disease (GD) (1, 2), although
severe, debilitating forms are rarer, with only 2–5% of pa-
tients developing severe, progressive proptosis (3). How-
ever, using sensitive means, such as ultrasound, computer-
ized tomography, or intraocular pressure measurement,
evidence of extraocular infiltration can be detected in virtu-
ally all GD patients (3–5). Rather than being a complication
of GD, GO is a concomitant expression of the same under-
lying pathological autoimmune process directed against
cross-reactive autoantigens in the thyroid and retrobulbar
tissues (6–8). The resultant, primarily lymphocyte-medi-
ated, inflammatory response leads to the excessive produc-
tion of glycosaminoglycans by orbital fibroblasts (2, 7, 9).
Only a weak consensus exists on either the evaluation or
the management of GO. Two systems are routinely used for
evaluation. The NOSPECS index (N, no signs or symptoms;
O, only signs, no symptoms; S, soft tissue involvement; P,
proptosis; E, extraocular muscle involvement; C, corneal in-
volvement; S, sight loss) gives a global estimate of the se-
verity of the various symptoms, although it has been criti-
cized for providing only a mean assessment, so that many
experts propose evaluating the various symptoms separately
(10). It was partly in response to this type of criticism that
Mourits et al. (11) developed the Clinical Activity Scale
(CAS), which gives a measure of disease activity.
It is generally accepted that corticosteroids and/or orbital
radiotherapy should be considered as treatments for estab-
lished moderately severe to severe GO, both of which are
associated with some adverse reactions (12). Moreover, a
successful outcome is far from certain (7, 13, 14). There exists,
therefore, a genuine need for new effective and safe modal-
ities that can be used in the early stages of GO to prevent
deterioration to a more severe form.
Somatostatin is an endogenous cyclic peptide that has
broadly inhibitory activity on a variety of different systems
(15). Many different cell types, including fibroblasts and
lymphocytes, are known to express somatostatin receptors,
and the level of expression of high affinity somatostatin
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receptors in retrobulbar tissue is known to correlate with the
clinical activity of GO (6). The rationale for using somatosta-
tin analogs to treat GO is based on the putative capacity of
these peptides to inhibit lymphocyte activation, prolifera-
tion, and cytokine production (16, 17). Moreover, somatosta-
tin is known to inhibit the release of IGF, the production of
which by fibroblasts has been implicated in the pathogenesis
ofGO (18), even if serum levels of IGF are normal in the active
forms of GO, suggesting intraorbital overproduction (19). A
number of preliminary open studies have suggested that
somatostatin analogs might be effective against GO. In these
studies the main effect of octreotide or lanreotide was the
attenuation of soft tissue and extraocular muscle involve-
ment in a majority of the patients treated (in most cases for
a period of 3 months) (20–22), although in few open studies
a beneficial effect was also observed on proptosis (23, 24).
However, the studies conducted to date have addressed
highly disparate patient populations at different stages of the
disease, they have lacked appropriate controls, and the num-
bers studied have been small, so any conclusions to be drawn
from these studies are necessarily provisional (18). Because
a significant proportion of patients with GO improve spon-
taneously, clinical trials designed to test the efficacy of new
treatments in thyroid-associated ophthalmopathy should be
scrupulously controlled to allow for the natural tendency
toward remission (25).
Hence, there was a need for a randomized, placebo-con-
trolled, double-blind study to investigate the efficacy of so-
matostatin analogs in the treatment of GO. In this study it
was decided to use the long-acting release formulation of
octreotide (octreotide-LAR) in patients with mild, active GO
with the aim of preventing additional deterioration and pre-
cluding the need for more aggressive therapeutic modalities,
such as glucocorticoids or radiotherapy.
Subjects and Methods
Study design and objectives
A double-blind, placebo-controlled, randomized study was con-
ducted. Patients were recruited and treated at 13 centers (10 in France
and three in Belgium). Randomization on a 1:1 basis to either octreotide-
LAR or placebo was centralized and was stratified by sex and current
smoking status (smoking being defined as the consumption ofmore than
five cigarettes per day).
Between inclusion and the beginning of treatment, an 8-wk interval
was programmed to confirm the stability of euthyroidism.After baseline
monitoring on the first day of treatment, patientswere examined at 4-wk
intervals throughout the 16-wk treatment period and then again in a
follow-up evaluation 6months after the beginning of treatment. Adverse
events occurring at any time in the 6-month study period were recorded
and analyzed.
Patients
Eligible for the study were euthyroid outpatients with clinically ac-
tive, mild to moderate GO. The diagnosis of GO was based on the
presence of at least two of the following signs: retraction of the eyelid
(a palpebral fissure wider than 11 mm or a distance of 7 mm between
the edge of the lower eyelid and the center of the pupil), palpebral
edema, proptosis, and impaired ocular mobility with increased intraoc-
ular pressure on upgaze associated with enlargement of at least one
oculomotor muscle. Mild to moderate disease severity was defined
using the NOSPECS scale as either minimal to moderate soft tissue
involvement (class 2, grades a–c) or minimal to moderate soft tissue
involvement (grade 2a or b) coupledwithmild proptosis (grade 3a),mild
extraocularmuscle involvement (grade 4a), ormild corneal involvement
(grade 5a). Clinically active disease (based on eye pain, ocular or eyelid
erythema, conjunctival or eyelid edema, and worsening of proptosis)
was defined as a score of 3 or more on the 10-item CAS proposed by
Mourits et al. (11). Stable euthyroidism was defined by blood concen-
trations of free T4, free T3, and TSH in the normal range throughout the
study period.
Exclusion criteria included severe refractive abnormalities or any
other eye problem that might interfere with the accuracy of the study
measurements, gallstones, or a history of treatmentwithin the preceding
6 months with systemic corticosteroids, immunosuppressive drugs, ra-
diotherapy, or chemotherapy.
Study treatment
Octreotide-LAR (Sandostatin LAR, supplied by Novartis, Rueil Mal-
maison, France) was supplied in vials containing 30 mg lyophilisate for
reconstitution to a volume of 2 ml. Treatments (octreotide-LAR or pla-
cebo) were administered at 4-wk intervals over 4 months (d 0 and wk
4, 8, and 12) by im injection.
Concomitant medications
Stable euthyroidism was a formal requirement in the protocol, so
exogenous T4 at the appropriate dosage was permitted throughout the
study period, as were antithyroid drugs (carbimazole, benzylthiouracil,
and propylthiouracil), as long as the dosage of the latter was not sig-
nificantly modified during the study. Also permitted were topical prod-
ucts (artificial tears, ocular lubricants, and antibiotic eye drops). For-
mally excluded were radiotherapy, chemotherapy, iv immunoglobulin,
immunosuppressants, anticoagulants, antiplatelet drugs, oral iodine/
iodide, lithium, and amiodarone.
Study assessments
The main end point was a binary success/failure criterion based on
changes in NOSPECS classification and CAS between baseline (d 0) and
the end of treatment (wk 16). Success was defined as a decrease in
NOSPECS class or grade only when CAS was unchanged or decreased;
failure was defined as either an increase in CAS or an absence of change
or an increase in NOSPECS class or grade. If changes were recorded in
two different NOSPECS classes, the higher change was used to define
the result.
In addition to the main composite efficacy end point, in a secondary
analysis the groups were compared on the basis of overall changes in
CAS and in individual items of the ophthalmological examination, with
special attention paid to objective parameters (notably proptosis, as
measured using the Hertel exophthalmometer, and palpebral opening
and retraction). Furthermore, self-assessment was evaluated with two
validated quality of life questionnaires: one global, the SF-36 (26), and
the other specific to GO, the GO-QOL (27).
Thyroid function (blood levels of TSH, T4, and T3) was monitored
throughout the study period, and pertinent serological parameters (an-
tibodies against thyroglobulin, thyroperoxidase, and the TSH receptor)
were assayed at baseline and the end of treatment. All serum measure-
ments were performed in each center with commercial kits.
Somatostatin receptor scintigraphy was performed at baseline using
a -camera to acquire data on the anterior head and both profiles 4 and
18–24 h after the iv injection of [111In]pentreotide (220 MBq, 10 g;
octreoscan, Mallinckrodt, St. Louis, MO). The images were centrally
interpreted by two independent observers blinded to patient’s data. A
semiquantitative four-point score was used to classify the intensity of
uptake, as previously reported (28, 29): negative scintigraphy, uptake
indiscernible from background noise; , weakly positive scintigraphy,
uptake hardly to slightly discernible from background noise at 4 or 24 h;
, moderately positive scintigraphy, moderate uptake at 4 and 24 h; and
2, strongly positive scintigraphy, strong uptake at 4 h with enhance-
ment at 24 h. In the event of conflicting interpretations, the two observers
had to meet to agree to a consensus. The objective was to investigate the
reported correlation of this parameter with the CAS (30, 31) with a view
to evaluating the predictive power of this examination vis-a`-vis the
efficacy of octreotide treatment (32). In normal individuals, there is no
orbital uptake of octreoscan.
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Extraocular muscle involvement, an almost typical sign in GO, was
specifically investigated at baseline and at month 4 by nuclear magnetic
resonance (NMR) measurement of the lateral, medial, inferior, and su-
perior rectusmuscles (33–35) with a T1-weighted and a T2 gradient echo
sequence. Results were read centrally by an independent expert and
analyzed for correlations with other parameters, notably baseline scin-
tigraphic data and CAS, antibody titers, and outcome.
For the safety analysis, details of all adverse events occurring at any
time in the 6-month study period were collected.
Sample size and statistical analysis
Assuming a success rate of 30% in the placebo group and a difference
of 35% in the treated group compared with placebo, it was calculated
that 37 patients/treatment group had to be recruited to guarantee a
power of 0.80. However, due to the very slow recruitment, the study had
to be stopped after 51 patients had been randomized (inclusion duration
of 18 months).
The main efficacy analysis was based on the intention to treat pop-
ulation (all patients who received at least one dose of the test treatment
and for whom pretreatment and end of treatment data were available
for at least one efficacy parameter) and comparison of the baseline
reading with the last measurement during treatment. Parallel analyses
conducted on the per protocol population gave similar results. All sta-
tistical analyses were two-sided, with a critical significance level of 5%.
For the main end point, the effect of treatment was analyzed using the
Mantel Haenszel test adjusted for sex and smoking status. Because
stratification of randomization according to sex and smoking resulted in
unbalanced distribution between the two groups at certain centers, no
center-adjusted analysis was attempted. For the secondary end points
discussed, changes in the two groups between baseline and the end of
either treatment or follow-up were compared using the Wilcoxon two-
sample test. All relevant ophthalmological parameters were evaluated
for both eyes andwere analyzed in twoways: themean of both eyes, and
with respect to the most severely affected eye at baseline (as defined by
the exophthalmometer measurement). Frequency tables were compiled
for adverse events, classified according to the standardWHO-ARTBody
System Dictionary and preferred terms. All laboratory results out of the
normal range were listed.
Ethics
All patients gave written, informed consent to participate, after hav-
ing been judged able to understand and comply with the requirements
of the study, which was conducted in accordance with the Helsinki
Declaration concerning medical research on human subjects (as
amended) and European Union Directive 91/507/EC. The protocol was
preapproved by the ethics committee of Lille University Hospital.
Results
Population
Enrolment began in January 2001, with the last patient
completing final evaluation in June 2003. Fifty-one patients
were recruited. The patient populations are described in
Table 1.
Demographic and background characteristics
The study population was representative of the GO pop-
ulation with respect to all key parameters, namely gender,
age, body weight, and the preponderance of GD of recent
onset. The orbitopathy in this population was of relatively
long standing (Table 2), but was still active (CAS,3; mean,
4.2  1.6). As shown in Table 2, the stratified centralized
randomization process generated two broadly comparable
treatment groups. There were no significant differences be-
tween the two groups.
Efficacy
No significant treatment effect emerged from the analysis
of the main composite efficacy end point (Table 3) regardless
of whether the analysis was conducted on the intention to
treat or the per protocol population. Considering the com-
ponents of the primary end point independently, a small
improvement was observed in CAS for patients treated with
octreotide-LAR and also in the group receiving placebo,
without any significant difference between the two groups.
No significant change was detected in either group in any of
the following ophthalmological parameters: palpebral
edema, oculomotor function, tear secretion, diplopia, oph-
thalmoscopy findings, and intraocular pressure. There was
a marginal tendency toward diminished soft tissue involve-
ment, but this was not associated with any difference be-
tween groups (not shown).
However, a stronger tendency toward reduction was ob-
served in the octreotide-LAR group in the proptosis com-
ponent of the NOSPECS classification in the form of a down-
ward shift in grade between baseline and the end of
treatment, with no such change recorded in the control
group. Furthermore, this trend persisted posttreatment. A
decrease of 2 mm or more in proptosis was observed in one
patient in each group at the end of the 4-month treatment
period and in four patients in the octreotide-LAR group, but
in only one patient in the placebo group at the end of the
study, i.e. 2 months posttreatment. Moreover, the apparent
improvement was statistically significant as observed in the
quantitative exophthalmometric measurements in the pa-
tient groups. Proptosis was decreased by the end of the
treatment period in the octreotide-LAR group, whereas no
change was measured in the placebo group. The difference
between the groupswas significant whether the analysis was
carried out on the mean of both eyes (P  0.027) or the most
severely affected eye alone (P  0.014). These data for the
most severely affected eye are presented in Fig. 1. A non-
significant, but parallel, change was detected in a related
parameter, namely, the opening of the upper eyelid, which
decreased from 0.4 to 0.1 mm in the octreotide-LAR group,
but increased from 0.6 to 0.7 mm in the placebo group.
TABLE 1. Study populations
Octreotide-LAR Placebo Total
Randomized (tolerance) 26 25 51
Intention to treat 25a 25 50
Per protocol 18 22 40
Major protocol violations 7 3 10
Unstable thyroid functionb 4 0 4
Other 3c 3d 6
Premature withdrawal 2 2 4
Insufficient efficacy 1 1 2
Other 1e 1f 2
a Inadequate efficacy data for one patient who withdrew from the
study after one dose of octreotide-LAR.
b TSH level of greater than 10 IU/ml detected at some point in the
study period.
c NOSPECS grade outside of stipulated range/CAS too low/end of
treatment monitoring outside of stipulated time frame.
d NOSPECS grade outside of stipulated range/no baseline oph-
thalmologic examination data.
e Due to an adverse event.
f Due to administrative problems.
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TABLE 2. Demographic and background characteristics of the randomized population
Octreotide-LAR (n  26) Placebo (n  25) Total (n  51)
Sex [no. (%)]
M 6 (23.1) 4 (16.0) 10 (19.6)
F 20 (76.9) 21 (84.0) 41 (80.4)
Age (yr), mean  SD 47.5  12.3 47.1  12.6 47.3  12.3
Height (cm), mean  SD 162  7 165  9 164  8
Weight (kg), mean  SD 63.5  12.8 65.3  15.6 64.4  14.1
Smoking status, [no. (%)]
Nonsmokers 9 (34.6) 12 (48.0) 21 (41.2)
Former smokers 6 (23.1) 6 (24.0) 12 (23.5)
Current smokersa 11 (42.3) 7 (28.0) 18 (35.3)
Nature of thyroid disease
GD [no. (%)] 25 (96.2) 24 (96.0) 49 (96.1)
History in months [mean  SD (range)] 29.0  27.02 (4–101) 30.6  39.76 (5–165) 29.8  33.51
Hashimoto’s disease [no. (%)] 1 (3.8) 2 (8.0) 3 (5.9)
History 303 32 and 118 151.0  138.48
History of GO in months, mean  SD 19.8  22.1 22.1  32.3 21.0  27.3
[range, median] [3–80, 12.0] [3–165, 11.0]
Treatment for thyroid disease [no. (%)]
Concomitant
None 1 (3.8) 2 (8.0) 3 (5.9)
Antithyroid drugs 15 (57.7) 16 (64.0) 31 (60.8)
T4 21 (80.8) 19 (76) 40 (78.4)
Previous treatment
None 2 (7.7) 7 (28.0) 9 (17.6)
Thyroidectomy 4 (15.4) 4 (16) 8 (15.7)
Antithyroid drugs 20 (76.9) 14 (56) 34 (66.7)
Iodine [131I] 4 (15.4) 0 4 (7.8)
a Consumption of more than five cigarettes per day.
TABLE 3. Efficacy parameters (intention-to-treat population)
Octreotide-LAR Placebo Pa
Primary (composite success/failure) end point
End of treatmentb (n  25) (n  25)
Success [no. (%)] 7 (28.0) 11 (44.0) 0.30
Failure [no. (%)] 18 (72.0) 14 (56.0)
End of study (n  24) (n  24)
Success [no. (%)] 9 (37.5) 11 (45.8) 0.50
Failure [no. (%)] 15 (62.5) 13 (54.2)
Pc
Selected secondary end points
CAS
Baseline 4.2  1.61d 4.5  1.26d
End of treatmentb 3.1  1.7d 3.4  1.9d 0.80
End of study 2.5  1.1e 3.2  2.5e 0.94
Proptosis (mm)
Mean for both eyes
Baseline 21.1  1.92d 20.3  1.96d
End of treatmentb 20.7  2.19d 20.5  2.03d 0.027
End of study 20.3  1.97 20.3  2.13 0.18
Most severely affected eyef
Baseline 21.4  2.09d 20.7  1.92d
End of treatmentb 20.6  2.28d 20.7  2.23d 0.014
End of study 20.6  2.14e 20.5  2.34e 0.17
Octreotide-LAR Placebo
NOSPECS proptosis profile
Baseline3end of treatment3end of study 0: 36%348%350% 0: 24%324%329.2%
A: 56%340%344% A: 68%364%362.5%
B: 8%312%34.2% B/C: 8%312%3 8.4%
a Mantel Haenszel test stratified by sex and smoking status to compare with difference vis-a`-vis baseline.
b End of treatment; last measurement during treatment (after 12 or 16 wk of treatment).
c Wilcoxon two-sample test to compare with difference vs. baseline.
d n  25.
e n  24.
f That with the higher exophthalmometer reading at baseline.
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Furthermore, the difference in ocular pressure between the
primary and upgaze positionswas slightly improved after 16
wk of treatment (from 2.8 to 2.7 mm Hg), whereas it dete-
riorated over the same period in the placebo group (from 3.9
to 4.3 mm Hg).
Extraocularmuscular involvementwas directly addressed
by NMR measurement of the lateral, medial, inferior, and
superior rectus muscles at baseline and at the end of treat-
ment. The presence of at least one muscle with T2 gradient
echo sequence hypersignal, a parameter related to inflam-
mation, was found at baseline in only seven of 25 patients in
both octreotide-LAR and placebo groups. Over the course of
octreotide-LAR treatment, the frequency of T2 hypersignal
diminished in the treated group in all four muscles (inferior,
25% to 20.8%; lateral, 16.7% to 4.2%; median, 25% to 20.8%;
superior, 20.8% to 12.5%), whereas no such consistent change
was observed in the placebo group. A global overview, ob-
tained by calculating the total surface areas for the four
muscles using the equation (length  height)2/16  3.14,
illustrates the slight, but nonsignificant, improvement in-
duced by octreotide-LAR (220  39 to 181  15 mm2; P 
0.05; Fig. 2). No significant changes were observed in self-
assessment with either the SF-36 questionnaire or the GO-
QOL questionnaire.
Predictive value of somatostatin receptor scintigraphy and
magnetic resonance imaging (MRI)
The semiquantitative results of orbital [111In]pentetreotide
uptake did not show any significant correlation with the
baseline CAS (r  0.21; P  0.147), nor was any correlation
observed between the strength of the initial signal and the
response to treatment (Table 4). It is worth noting that 46%
of the patients in the octreotide-LAR group and 40% in the
placebo group produced no signal. Baseline MRI detected a
T2 hypersignal in only seven of 25 patients in both octreotide-
LAR and placebo groups. The presence of T2 hypersignal
correlated significantlywith [111In]pentetreotide uptake (P
0.032); there was also some, but a nonsignificant, correlation
with the CAS (mean score, 5.00 2.08 in the T2 patients vs.
4.09  1.04 in the T2 patients; P  0.21).
Thyroid function and serology
The levels of TSH and free T4 remained stable in both
groups throughout the study period. The level of antibodies
directed against the TSH receptor decreased significantly in
both groups (P  0.005), with no significant difference be-
tween the groups (P  0.35). Antibody levels did not cor-
relate with any inflammatory parameter related to disease
activity (CAS or MRI T2 signal).
Safety
Octreotide-LAR induced the expected profile of minor
side-effects: essentially temporary, mild gastrointestinal per-
turbations (diarrhea, abdominal pain, nausea, and constipa-
FIG. 2. Total muscle area for the eye with the more severe baseline
exophthalmos at inclusion (M0) and after 4months (M4). Muscle area
is derived fromNMR evaluation. *,Wilcoxon’s rank-sum test between
treatment groups on change from baseline.
FIG. 1. Mean proptosis value for the worst eye at
inclusion (M0), 2months (M2), and 4months (M4)
of treatment period and 2 months after the end of
the therapy (M6). *, Wilcoxon’s rank-sum test
between treatment groups at the end of treat-
ment.
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tion). Nevertheless, a serious adverse event attributed to the
treatment was one case of gallstones that was confirmed on
coelioscopic cholecystectomy; the pretreatment ultrasound
examination carried out on this patient 9 months before the
study had revealed no abnormality.
Discussion
In this placebo-controlled, double-blind study of the effi-
cacy of octreotide-LAR in the treatment of mildly active GO,
no significant effect of somatostatin analog treatment was
detected for the main efficacy end point, a composite pa-
rameter in which success is defined by decreased disease
severity coupledwith unchanged or decreased disease activity.
Mention should be made of possible bias in the study. 1)
There were more active smokers in the octreotide-LAR than
in the placebo group. 2) More patients in the placebo group
had not received any form of treatment in the past for GD,
suggesting that their disease might have been of more recent
onset. 3) Four patients in the octreotide-LAR group had been
previously treated with radioactive iodine compared with
none in the placebo group. 4) As a result of different strat-
egies for the management of GD in the various centers, the
protocol requirement for stable euthyroidism throughout the
duration of the study was violated for a short while in four
cases, all in the octreotide-LAR group. All of these factors are
known to exacerbate GO or compromise the outcome of
treatment: smoking (36, 37), stage of disease (38), iodine
radiotherapy (39), and unstable thyroid function (25). Fur-
thermore, the diseasewas of relatively long standing in those
patients with a mean history of almost 2 yr and a median of
12 months. Probably the longer the duration of GO, the
weaker the inflammatory activity of the disease (40). Al-
though aCAS ofmore than 3was a prerequisite for inclusion,
the fact that a large proportion of the patients in both groups
may have been at a relatively late stage of the disease is also
supported by both the baseline scintigraphic data, with 43%
of the patients giving a completely negative signal, and the
T2-weighted MRI scan results, with only 28% of patients
giving a positive signal at the beginning of the study.
Although correlation has been reported between [111In]
pentetreotide uptake and the presence of a MRI T2 hyper-
signal, we failed to observe any such correlation between
uptake and either baseline CAS (21, 32, 41) or response to
treatmentwith somatostatin analogs (42). In previous studies
the populations were probably at a more active stage of the
disease, as evidenced by scintigraphic data (29).
Somatostatin is a pleiotropic effector molecule with char-
acterized effects on thyroid function (43). In this study no
significant differences were observed between the treated
and control groups in a variety of parameters of thyroid
function, notably the concentrations of T4, T3, and TSH in the
blood. Predictably, no effects of octreotide-LAR on thyroid
function could be detected in this study, due to the stronger
effects of the antithyroid drugs. Moreover, levels of antibod-
ies directed against the TSH receptor decreased in a signif-
icant fashion in both groups, with no difference observed
between them. In contrast to a prior observation (6), there
was no correlation between antibody levels and any of the
inflammatory parameters related to disease activity (CAS or
MRI T2 signal).
Despite the lack of any difference between the two groups
with respect to themain efficacy endpoint, a significant effect
of treatment was observed in one key symptom of GO,
namely proptosis. Proptosis, which is particularly amenable
to objective measurement, was mildly decreased in the
treated group, but not in untreated patients. The effect at
the end of treatment was statistically significant for both the
mean of the two eyes and the most severely affected eye
alone, and the improvementwas sustained through 2months
after the end of treatment. In a study such as this in which
a great number of different individual variables are tested
(with the ophthalmological examination alone generating
five objective variables and five other analyzable variables),
the dangers of multiple testing are an important issue (44).
If 10 variables are tested with a critical significance level of
5%, it is likely that a significant difference will be observed
in at least one of them even if the null hypothesis is true.
However, in this study strong circumstantial evidence that
the beneficial effect of treatment on proptosis is indeed a real
one is provided by the concordance of a whole series of results
for other, closely relatedparameters, namelyNOSPECS class III
grade, opening of the upper eyelid, and the difference in ocular
pressure between primary position and upgaze. Furthermore,
MRIdimensioningdetected a tendency towarddiminished soft
tissue involvement, theprocess that underlies proptosis, during
and after octreotide-LAR treatment. The total area correspond-
ing to the cumulate surface of the intraorbital muscles was
reduced, but not significantly. This suggests that the reduction
of proptosis arose from a reduction of both muscular and ad-
ipose intraorbital contents.
None of these other individual differences is significant,
but all are in the same direction, pointing to real therapeutic
efficacy vis-a`-vis proptosis, one of the most clinically signif-
icant symptoms of GO and certainly the most debilitating in
cosmetic and, therefore, psychological terms. In agreement
with these data, the double-blind, placebo-controlled trial of
octreotide-LAR in thyroid-associated orbitopathy conducted
in Great Britain and Germany also mentioned a modest ben-
efit of the somatostatin analog, but it was only significant on
exophthalmos (45). The slight effectiveness of octreotide-
TABLE 4. Predictive value of somatostatin receptor scintigraphy
(SRS) vis-a`-vis the efficacy of octreotide
Baseline SRS signal Outcome Octreotide-LAR(n  24)
Placebo
(n  25)
Negativea Success 4 (16.8) 4 (16.0)
Failure 7 (29.2) 6 (24.0)
Weakly positiveb Success 2 (8.3) 2 (8.0)
Failure 3 (12.5) 3 (12.0)
Moderately positivec Success 0 5 (20.0)
Failure 2 (8.3) 5 (20.0)
Strongly positived Success 1 (4.2) 0
Failure 5 (20.8) 0
Values are the number of subjects (percentage).
a Negative: uptake indiscernible from background noise.
b Weakly positive: uptake hardly to slightly discernible from back-
ground noise at 4 or 24 h.
c Moderately positive: Moderate uptake at 4 and 24 h.
d Strongly positive: strong uptake at 4 hwith enhancement at 24 h.
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LAR might be dependent upon its restricted specificity [so-
matostatin receptor 2 (SstR2) and SstR5]. Because other SstR
subtypes are also expressed in resident and infiltrating cells
in the orbit of GO patients (17), the potentiality of new uni-
versal analogs, such as SOM 230, has to be tested in this
condition (46).
No consensus exists on the most clinically relevant pa-
rameters for the evaluation of GO, a lack the multicenter
European Group on Graves’ Orbitopathy is bound to correct
(47). Pertinently, one of the findings of the first large-scale
review conducted by this group is that the severity of prop-
tosis tends to be underestimated in the current NOSPECS
classification system, with class 3 signs found in only 38% of
patients, reflecting the ill-chosen proptosis cut-off point of 23
mm. The upper limit of normal proptosis values in Cauca-
sians is 19 mm (mean  sd), and 63% of our patients had
Hertel readings of 21 mm or greater, suggesting that the
current NOSPECS classification underestimates the severity
of this sign. Thus, in our study perhaps the primary endpoint
was ill chosen, but the EuropeanGroup onGraves’ Orbitopa-
thyworkmay lead to the definition ofmore pertinent criteria.
Nevertheless, the solid, sustained effect on proptosis of just
16 wk of octreotide-LAR treatment is an encouraging pre-
liminary result in light of the serious lack of therapeutic
options for this condition. Future larger-scale studies are
needed to confirm these results and to generate complete
data on the risk to benefit ratio of the somatostatin analogs
in this indication.
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